Discovery of Lung Cell "Switch" Paves Way for Regenerative Treatments

Researchers at Mayo Clinic have identified a molecular "switch" within alveolar type 2 (AT2) cells that dictates whether these cells focus on repairing lung tissue or defending against infections. This discovery, published in *Nature Communications*, reveals that AT2 cells, which are crucial for maintaining lung health, cannot perform both functions simultaneously. Douglas Brownfield, Ph.D., the senior author of the study, emphasized the significance of this division of labor, stating, “Some commit to rebuilding, while others focus on defense. That division of labor is essential.”

SciTechDaily

AT2 cells are vital for lung function as they produce proteins that keep air sacs open and act as reserve stem cells to replace alveolar type 1 (AT1) cells. However, in conditions such as pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and severe viral infections like COVID-19, these cells often fail to regenerate effectively. The research team utilized single-cell sequencing and imaging techniques to trace the life cycle of AT2 cells, discovering that these cells remain adaptable for one to two weeks post-birth before settling into a specialized state. This transition is regulated by a molecular circuit involving three key factors: PRC2, C/EBP?, and DLK1.

SciTechDaily

The study found that C/EBP? acts as a clamp that restricts stem cell behavior in adult lungs. For AT2 cells to regenerate tissue after injury, they must release this clamp. This mechanism also explains why infections can impede healing, as the prioritization of immune defense over tissue repair can delay recovery in patients with chronic lung diseases.

SciTechDaily

The findings suggest new avenues for regenerative therapies aimed at enhancing lung repair mechanisms. Adjusting C/EBP? activity could potentially improve the ability of AT2 cells to rebuild lung tissue and reduce scarring associated with pulmonary fibrosis. Dr. Brownfield noted, “This research brings us closer to being able to boost the lung’s natural repair mechanisms, offering hope for preventing or reversing conditions where currently we can only slow progression.”

SciTechDaily

The research aligns with Mayo Clinic’s Precure initiative, which focuses on early disease detection and intervention, and the Genesis initiative, aimed at preventing organ failure through regenerative medicine. Researchers are currently exploring methods to remove the restrictive clamp from human AT2 cells, cultivate them in laboratory settings, and investigate their application in cell replacement therapies.

SciTechDaily

• “We were surprised to find that these specialized cells cannot do both jobs at once,” — Douglas Brownfield, Ph.D.

SciTechDaily

• “When we think about lung repair, it’s not just about turning things on — it’s about removing the clamps that normally keep these cells from acting like stem cells,” — Douglas Brownfield, Ph.D.

SciTechDaily

• “This research brings us closer to being able to boost the lung’s natural repair mechanisms, offering hope for preventing or reversing conditions where currently we can only slow progression,” — Douglas Brownfield, Ph.D.

SciTechDaily